Trial Profile
A Randomized, Double-Mask, Placebo-Controlled, Dose Response, Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Diabetic Patients' Corneal Wounds Resulting From Epithelial Debridement During Vitrectomy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2015
Price :
$35
*
At a glance
- Drugs Timbetasin (Primary)
- Indications Corneal injuries; Diabetic complications
- Focus Adverse reactions
- Sponsors RegeneRx Biopharmaceuticals
- 17 Sep 2014 New trial record